{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:43:19Z","timestamp":1768322599680,"version":"3.49.0"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The burden of cervical cancer caused by human papillomavirus (HPV) is high in Latin America. The suboptimal HPV vaccination coverage in adolescents could be improved by pediatric immunization. HPV vaccination has not yet been reported in girls &lt;9 years of age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This ongoing phase III, controlled, randomized, single-blind, multicenter study conducted in Colombia, Mexico and Panama (NCT01627561) evaluated the safety and immunogenicity of AS04-HPV-16\/18 vaccine in 4\u20136-year-old girls. Healthy girls (randomized 1:1) received either 2 doses of AS04-HPV-16\/18 vaccine (HPV group, N=74) or 1 dose of each measles-mumps-rubella and diphtheria-tetanus-acellular-pertussis vaccines (control group, N=74) 6 months apart. We report the safety and serum anti\u2013HPV-16 and anti\u2013HPV-18 antibodies (measured by enzyme-linked immunosorbent assay) up to 6 months postvaccination, that is, month (M) 12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Injection site pain was the most frequently reported solicited local symptom in HPV vaccinees. The incidence of other solicited and unsolicited symptoms after each vaccination was similar between the HPV and control group. Until M12, 1 girl in the HPV group and 2 in the control group reported serious adverse events; all serious adverse events were assessed as unrelated to study vaccines. No potential immune-mediated diseases were identified. All girls seroconverted for both antigens after 2 doses of AS04-HPV-16\/18. In initially seronegative girls, anti\u2013HPV-16 geometric mean concentrations were 20080.0 enzyme-linked immunosorbent assay units (EU)\/mL at M7 and 3246.5 EU\/mL at M12; anti\u2013HPV-18 geometric mean concentrations were 10621.8 EU\/mL at M7 and 1216.6 EU\/mL at M12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Two-dose vaccination with AS04-HPV-16\/18 was well tolerated and induced adequate antibody responses in 4\u20136-year-old girls.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000001871","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T12:31:46Z","timestamp":1518179506000},"page":"e93-e102","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Safety and Immunogenicity of the HPV-16\/18 AS04-adjuvanted Vaccine in 4\u20136-year-old Girls"],"prefix":"10.1097","volume":"37","author":[{"given":"Lan","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes Macias","family":"Parra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor Y.","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albino Salas","family":"Cespedes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Angelica","family":"Granados","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Luque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Damaso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Mercedes","family":"Castrejon Alba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Romano-Mazzotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Struyf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260107","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s13669-015-0137-8","article-title":"Epidemiology and burden of disease associated with HPV infection.","volume":"4","author":"Vaccarella","year":"2015","journal-title":"Current Obstetrics Gynecol Reports"},{"key":"R2-20260107","doi-asserted-by":"crossref","first-page":"104","DOI":"10.21149\/spm.v58i2.7779","article-title":"Cancer patterns, trends and projections in Latin America and the Caribbean: a global context.","volume":"58","author":"Bray","year":"2016","journal-title":"Salud Publica Mex"},{"key":"R3-20260107","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer.","volume":"55","author":"Bosch","year":"2002","journal-title":"J Clin Pathol"},{"key":"R4-20260107","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S1470-2045(05)70086-3","article-title":"Carcinogenicity of human papillomaviruses.","volume":"6","author":"Cogliano","year":"2005","journal-title":"Lancet Oncol"},{"key":"R5-20260107","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"R6-20260107","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/jnci\/92.9.690","article-title":"Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis.","volume":"92","author":"zur Hausen","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R7-20260107","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1016\/j.vaccine.2008.05.064","article-title":"Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia.","volume":"26(suppl 10)","author":"Bosch","year":"2008","journal-title":"Vaccine"},{"key":"R8-20260107","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"R9-20260107","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer.","volume":"348","author":"Mu\u00f1oz","year":"2003","journal-title":"N Engl J Med"},{"key":"R10-20260107","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ijc.22527","article-title":"Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.","volume":"121","author":"Smith","year":"2007","journal-title":"Int J Cancer"},{"key":"R11-20260107","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"R12-20260107","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women.","volume":"102","author":"Mu\u00f1oz","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"(suppl 3)","key":"R13-20260107","first-page":"S3\/35","article-title":"Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6\/11 disease.","volume":"24","author":"Lacey","year":"2006","journal-title":"Vaccine"},{"key":"R14-20260107","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"R15-20260107","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/CVI.00591-14","article-title":"Efficacy of human papillomavirus 16 and 18 (HPV-16\/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.","volume":"22","author":"Apter","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"R16-20260107","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum Vaccin"},{"key":"R17-20260107","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.4161\/hv.7.12.18282","article-title":"Comparison of the immunogenicity of the human papillomavirus (HPV)-16\/18 vaccine and the HPV-6\/11\/16\/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years.","volume":"7","author":"Einstein","year":"2011","journal-title":"Hum Vaccin"},{"key":"R18-20260107","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.4161\/hv.36117","article-title":"Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18-45 years: follow-up through month 48 in a phase III randomized study.","volume":"10","author":"Einstein","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"R19-20260107","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.4161\/hv.36121","article-title":"Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.","volume":"10","author":"Einstein","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"R20-20260107","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jadohealth.2010.02.006","article-title":"Safety and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.","volume":"46","author":"Medina","year":"2010","journal-title":"J Adolesc Health"},{"key":"R21-20260107","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jadohealth.2007.02.015","article-title":"Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant.","volume":"40","author":"Pedersen","year":"2007","journal-title":"J Adolesc Health"},{"key":"R22-20260107","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ijc.25887","article-title":"Long-term persistence of systemic and mucosal immune response to HPV-16\/18 AS04-adjuvanted vaccine in preteen\/adolescent girls and young women.","volume":"129","author":"Pet\u00e4j\u00e4","year":"2011","journal-title":"Int J Cancer"},{"key":"R23-20260107","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1097\/INF.0000000000000460","article-title":"Long-term immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial.","volume":"33","author":"Schwarz","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R24-20260107","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jadohealth.2011.11.004","article-title":"Four-year follow-up of the immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years.","volume":"50","author":"Schwarz","year":"2012","journal-title":"J Adolesc Health"},{"key":"R25-20260107","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.4161\/hv.6.12.13399","article-title":"Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16\/18 AS04-adjuvanted vaccine.","volume":"6","author":"Schwarz","year":"2010","journal-title":"Hum Vaccin"},{"key":"R26-20260107","doi-asserted-by":"crossref","first-page":"958","DOI":"10.4161\/hv.7.9.15999","article-title":"Persistence of immune response to HPV-16\/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years.","volume":"7","author":"Schwarz","year":"2011","journal-title":"Hum Vaccin"},{"key":"R27-20260107","doi-asserted-by":"crossref","first-page":"6630","DOI":"10.1016\/j.vaccine.2008.09.049","article-title":"Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines.","volume":"26","author":"Verstraeten","year":"2008","journal-title":"Vaccine"},{"key":"R28-20260107","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1016\/j.vaccine.2014.04.005","article-title":"Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule.","volume":"32","author":"Boxus","year":"2014","journal-title":"Vaccine"},{"key":"R29-20260107","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.vaccine.2013.11.059","article-title":"Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16\/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months.","volume":"32","author":"Lazcano-Ponce","year":"2014","journal-title":"Vaccine"},{"key":"R30-20260107","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1080\/21645515.2015.1050570","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: results to month 12 from a randomized trial.","volume":"11","author":"Leung","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"R31-20260107","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/21645515.2015.1065363","article-title":"Sustained immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study.","volume":"12","author":"Romanowski","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"R32-20260107","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.4161\/hv.28022","article-title":"Immune response to the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study.","volume":"10","author":"Romanowski","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"R33-20260107","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.4161\/hv.7.12.18322","article-title":"Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study.","volume":"7","author":"Romanowski","year":"2011","journal-title":"Hum Vaccin"},{"key":"R34-20260107","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"key":"R36-20260107","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.vaccine.2013.01.028","article-title":"Female human papillomavirus (HPV) vaccination: global uptake and the impact of attitudes.","volume":"31","author":"Hopkins","year":"2013","journal-title":"Vaccine"},{"key":"R37-20260107","doi-asserted-by":"crossref","first-page":"F139","DOI":"10.1016\/j.vaccine.2012.05.039","article-title":"Human papillomavirus vaccine introduction\u2013the first five years.","volume":"30(suppl 5)","author":"Markowitz","year":"2012","journal-title":"Vaccine"},{"key":"R38-20260107","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1377\/hlthaff.27.2.487","article-title":"Immunization and the Millennium Development Goals: progress and challenges in Latin America and the Caribbean.","volume":"27","author":"Andrus","year":"2008","journal-title":"Health Aff (Millwood)"},{"key":"R43-20260107","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"R44-20260107","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3332\/ecancer.2015.577","article-title":"Epidemiology of cervical cancer in Latin America.","volume":"9","author":"Capote Negrin","year":"2015","journal-title":"Ecancermedicalscience"},{"key":"R46-20260107","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4161\/hv.5.5.7211","article-title":"Safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials.","volume":"5","author":"Descamps","year":"2009","journal-title":"Hum Vaccin"},{"key":"R47-20260107","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1586\/14760584.6.5.723","article-title":"GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.","volume":"6","author":"Gar\u00e7on","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"R48-20260107","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/pds.3593","article-title":"Post-licensure safety surveillance for human papillomavirus-16\/18-AS04-adjuvanted vaccine: more than 4\u2009years of experience.","volume":"23","author":"Angelo","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R49-20260107","doi-asserted-by":"crossref","first-page":"e0136789","DOI":"10.1371\/journal.pone.0136789","article-title":"The global epidemiology of impetigo: a systematic review of the population prevalence of impetigo and pyoderma.","volume":"10","author":"Bowen","year":"2015","journal-title":"PLoS One"},{"key":"R50-20260107","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2222.2011.03891.x","article-title":"Prevalence and diversity of allergic rhinitis in regions of the world beyond Europe and North America.","volume":"42","author":"Katelaris","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"R51-20260107","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S1473-3099(15)00132-2","article-title":"Prevalence of scabies and impetigo worldwide: a systematic review.","volume":"15","author":"Romani","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"R52-20260107","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jmv.1890470305","article-title":"Perinatal infection and persistence of human papillomavirus types 16 and 18 in infants.","volume":"47","author":"Cason","year":"1995","journal-title":"J Med Virol"},{"key":"R53-20260107","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/jmv.20874","article-title":"The seroprevalence of IgG antibodies to human papillomavirus (HPV) types HPV-16, HPV-18, and HPV-11 capsid-antigens in mothers and their children.","volume":"79","author":"Marais","year":"2007","journal-title":"J Med Virol"},{"key":"R54-20260107","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/(SICI)1099-1654(199901\/03)9:1<15::AID-RMV232>3.0.CO;2-Q","article-title":"High risk genital papillomavirus infections are spread vertically.","volume":"9","author":"Rice","year":"1999","journal-title":"Rev Med Virol"},{"key":"R55-20260107","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1600-0463.2010.02620.x","article-title":"Current concepts on human papillomavirus infections in children.","volume":"118","author":"Syrj\u00e4nen","year":"2010","journal-title":"APMIS"},{"key":"R56-20260107","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.pvr.2016.07.001","article-title":"Human papillomavirus (HPV) perinatal transmission and risk of HPV persistence among children: design, methods and preliminary results of the HERITAGE study.","volume":"2","author":"Trottier","year":"2016","journal-title":"Papillomavirus Res"},{"key":"R57-20260107","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/infdis\/jiw036","article-title":"Randomized open trial comparing 2-dose regimens of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years.","volume":"214","author":"Puthanakit","year":"2016","journal-title":"J Infect Dis"},{"key":"R58-20260107","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4161\/hv.29532","article-title":"Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.","volume":"10","author":"Naud","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"R59-20260107","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1940-6207.CAPR-13-0203","article-title":"Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.","volume":"6","author":"Safaeian","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"key":"R60-20260107","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/infdis\/jix154","article-title":"Sustained immunogenicity of 2-dose human papillomavirus 16\/18 AS04-adjuvanted vaccine schedules in girls aged 9-14 years: a randomized trial.","volume":"215","author":"Huang","year":"2017","journal-title":"J Infect Dis"},{"key":"R61-20260107","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1002\/cam4.1155","article-title":"Ten-year immune persistence and safety of the HPV-16\/18 AS04-adjuvanted vaccine in females vaccinated at 15\u201355 years of age.","volume":"6","author":"Schwarz","year":"2017","journal-title":"Cancer Med"},{"issue":"3 suppl","key":"R62-20260107","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ygyno.2009.01.011","article-title":"Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.","volume":"115","author":"David","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R63-20260107","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/10543406.2013.834917","article-title":"Model-based estimates of long-term persistence of induced HPV antibodies: a flexible subject-specific approach.","volume":"23","author":"Aregay","year":"2013","journal-title":"J Biopharm Stat"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201804000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T13:02:03Z","timestamp":1767790923000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201804000-00019"}},"subtitle":["Results to Month 12 From a Randomized Trial"],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001871","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}